We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Test Accurately Predicts End of Life for Lung Cancer Patients

By LabMedica International staff writers
Posted on 01 Mar 2023

Lung cancer continues to be the leading cause of cancer-related deaths for both men and women around the globe. More...

This deadly disease can affect its victims in various ways, such as through tumor growth and blood clotting. However, all of the possible factors that lead to death of a lung cancer patient have yet to be fully investigated. A new study has found that lung cancer patients can have their risk of mortality accurately predicted within the last four weeks of life by analyzing their urine. This information gives both the patient and their families the chance to prepare for the end of life, while also providing clinicians with more detailed data to inform their care and medication plans. Furthermore, this method can lead to the cessation of potentially intrusive tests and treatments and provide an easier transition to comfortable palliative care.

In the study, researchers at University of Liverpool (Liverpool, UK) found that it is possible to measure metabolic changes in the last month before a patient passes away in order to successfully predict their date of death, with the accuracy improving as the time of death approaches. Common biomarkers have been identified in patients dying from cancers, and the team specifically identified changes in volatile organic compounds. After analyzing urine samples of 144 lung cancer patients in their last few weeks of life via gas chromatography mass spectrometry, it was concluded that 37 volatile organic compounds showed such extreme changes that it was possible to draw significant predictions about their risk of death, which was categorized as low, medium, and high. The results in the 30 day window were found to have "excellent" probability values.

The research team has suggested that the findings can be utilized by clinicians to make more accurate predictions for patients who are suffering from terminal lung cancer. These metabolic changes are exclusive to terminal lung cancer, and the team is confident that future studies into other terminal cancers and even critical care settings will reveal biomarker changes that could further aid in their predictions. Additional studies are already being conducted by the team in order to validate and refine their models.

“Predicting when patients with advanced cancer are likely to die is challenging and no accurate test is available to determine this,” said co-author Professor Chris Probert, a consultant gastroenterologist at the Royal Liverpool University Hospital and Professor of Gastroenterology at the University of Liverpool. “This is the first study to use a metabolomics approach to investigate the dying process in the last weeks of life. The findings provide evidence to support the hypothesis that there are specific metabolic changes associated with the dying process in cancer.”

Related Links:
University of Liverpool


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Gut microbes may help in recognizing and treating pancreatic cancer (Photo courtesy of Adobe Stock)

Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. Now, a new international collaborative study suggests... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.